GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PTC Therapeutics Inc (NAS:PTCT) » Definitions » Cyclically Adjusted PB Ratio

PTCT (PTC Therapeutics) Cyclically Adjusted PB Ratio : 20.11 (As of May. 28, 2025)


View and export this data going back to 2013. Start your Free Trial

What is PTC Therapeutics Cyclically Adjusted PB Ratio?

As of today (2025-05-28), PTC Therapeutics's current share price is $47.86. PTC Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $2.38. PTC Therapeutics's Cyclically Adjusted PB Ratio for today is 20.11.

The historical rank and industry rank for PTC Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

PTCT' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 3.43   Med: 6.97   Max: 21.32
Current: 20.47

During the past years, PTC Therapeutics's highest Cyclically Adjusted PB Ratio was 21.32. The lowest was 3.43. And the median was 6.97.

PTCT's Cyclically Adjusted PB Ratio is ranked worse than
95.81% of 669 companies
in the Biotechnology industry
Industry Median: 1.48 vs PTCT: 20.47

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

PTC Therapeutics's adjusted book value per share data for the three months ended in Mar. 2025 was $-2.345. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $2.38 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


PTC Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for PTC Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PTC Therapeutics Cyclically Adjusted PB Ratio Chart

PTC Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 6.17 6.16 5.61 16.85

PTC Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.56 7.86 11.13 16.85 21.42

Competitive Comparison of PTC Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, PTC Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PTC Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PTC Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where PTC Therapeutics's Cyclically Adjusted PB Ratio falls into.


;
;

PTC Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

PTC Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=47.86/2.38
=20.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PTC Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, PTC Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-2.345/134.9266*134.9266
=-2.345

Current CPI (Mar. 2025) = 134.9266.

PTC Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201506 7.339 100.684 9.835
201509 7.936 100.392 10.666
201512 6.663 99.792 9.009
201603 5.778 100.470 7.760
201606 4.859 101.688 6.447
201609 4.103 101.861 5.435
201612 3.500 101.863 4.636
201703 2.938 102.862 3.854
201706 4.109 103.349 5.364
201709 3.518 104.136 4.558
201712 3.759 104.011 4.876
201803 3.595 105.290 4.607
201806 5.728 106.317 7.269
201809 7.656 106.507 9.699
201812 6.931 105.998 8.823
201903 8.780 107.251 11.046
201906 8.324 108.070 10.393
201909 10.777 108.329 13.423
201912 9.596 108.420 11.942
202003 8.425 108.902 10.438
202006 8.514 108.767 10.562
202009 7.535 109.815 9.258
202012 6.913 109.897 8.487
202103 4.156 111.754 5.018
202106 2.786 114.631 3.279
202109 1.485 115.734 1.731
202112 0.020 117.630 0.023
202203 -1.270 121.301 -1.413
202206 -2.548 125.017 -2.750
202209 -3.158 125.227 -3.403
202212 -4.748 125.222 -5.116
202303 -6.182 127.348 -6.550
202306 -7.691 128.729 -8.061
202309 -8.890 129.860 -9.237
202312 -10.812 129.419 -11.272
202403 -11.662 131.776 -11.941
202406 -12.746 132.554 -12.974
202409 -13.701 133.029 -13.896
202412 -14.131 133.157 -14.319
202503 -2.345 134.927 -2.345

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


PTC Therapeutics  (NAS:PTCT) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


PTC Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of PTC Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


PTC Therapeutics Business Description

Traded in Other Exchanges
Address
500 Warren Corporate Center Drive, Warren, NJ, USA, 07059
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
Executives
Lee Scott Golden officer: Chief Medical Officer 17199 N. LAUREL PARK DRIVE, SUITE 401, LIVONIA MI 48152
Eric Pauwels officer: Chief Business Officer 550 HILLS DRIVE, BEDMINSTER NJ 07921
Stephanie Okey director C/O ALBIREO PHARMA, INC., 10 POST OFFICE SQUARE, SUITE 502 SOUTH, BOSTON MA 02109
Mark Elliott Boulding officer: Exec. VP and CLO C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Allan Steven Jacobson director PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Neil Gregory Almstead officer: EVP Research Pharma Ops & Tech C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Pierre Gravier officer: CHIEF FINANCIAL OFFICER C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Matthew B. Klein officer: Chief Development Officer C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Christine Marie Utter officer: Principal Financial Officer C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Jerome B Zeldis director 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Michael Schmertzler director 110 WASHINGTON STREET, SUITE 1300, CONSHOHOCKEN PA 19428
Alethia Young director C/O GRAPHITE BIO, INC., 201 HASKINS WAY, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Bell William F. Jr. director C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Emma Reeve director C/O PAREXEL INTERNATIONAL CORPORATION, 195 WEST STREET, WALTHAM MA 02451
David P Southwell director C/O INOTEK PHARMACEUTICALS CORPORATION, 91 HARTWELL AVENUE, LEXINGTON MA 02421